|
Age (mean, SD), years
|
32.74 ± 5.12
|
|
Disease duration, median (IQR), years
|
4.5 (1.93–8.92)
|
|
MS subtype at onset of pregnancy, no. (%)
| |
|
RRMS
|
109 (93.96%)
|
|
Progressive, relapsing MS
|
7 (6.03%)
|
|
Relapses during 2 years before pregnancya
| |
|
0
|
52 (44.83%)
|
|
1
|
43 (37.07%)
|
|
≥ 2
|
21 (18.10%)
|
|
MS-related disability, no. (%)
| |
|
No disability
|
70 (60.34%)
|
|
Some disability but fully ambulatory
|
37 (31.89%)
|
|
Some ambulatory impairment
|
7 (6.03%)
|
|
Cane required
|
1 (0.86%)
|
|
Wheelchair required
|
1 (0.86%)
|
|
EDSS score before pregnancy, no. (%)
| |
|
0–0.5
|
56 (48.27%)
|
|
1–1.5
|
39 (33.63%)
|
|
2–2.5
|
14 (12.07%)
|
|
3–3.5
|
5 (4.31%)
|
|
≥ 4
|
2 (1.72%)
|
|
DMT use before pregnancy, no. (%)
| |
|
Never
|
18 (15.52%)
|
|
At the time of conception
|
23 (19.83%)
|
|
Within 1 year prior
|
75 (64.65%)
|
|
Type used within 1 year prior
| |
|
Interferon-beta
|
39 (33.62%)
|
|
Dimethyl fumarate
|
7 (6.03%)
|
|
Natalizumab
|
1 (0.86%)
|
|
Rituximab
|
9 (7.76%)
|
|
Ocrelizumab
|
4 (3.45%)
|
|
Fingolimod
|
13 (11.21%)
|
|
Teriflunomide
|
2 (1.72%)
|
|
Comorbidities other than MS
| |
|
Hypertension
|
8 (6.89%)
|
|
Diabetes mellitus
|
1 (0.86%)
|
|
Othersa
|
1 (0.86%)
|
